← Home / ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT)
Stock Analysis
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT)
ADPT
ADPT · Market data
22.57 -6.66%
Track ADPT in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when ADPT price is:
52W Range Position
88%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-08-02 14:45 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 24.18. Holding above 19.82 keeps the current thesis intact.
⚖️
✓
Fundamentals
Strong / Negative
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
19.82
↗
Break Above
Confirmation improves above resistance.
24.18
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 19.82
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
29
●
Financial Results
HIGH
ADPT reports financial results
On July 24, 2026, the Company’s Chief Scientific Officer and Co-founder, Dr.
8-K Filing • SEC EDGAR
JUL
29
●
Management / Board
HIGH
ADPT board and management update
On July 24, 2026, the Company’s Chief Scientific Officer and Co-founder, Dr.
8-K Filing • SEC EDGAR
JUN
22
$
Debt Financing
HIGH
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
• Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility • Additional proceeds used to pay for the capped call with a premium of 100% and to repurchase $25 million of common stock to reduce potential dilution • Remaining capital to be used for general corporate purp...
8-K Filing • SEC EDGAR
What's Driving ADPT?
📈 Technical recovery is improving
Momentum is Neutral. Watch 24.18 for confirmation and 19.82 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
Below 19.82
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
56.6
Price Chart
ADPT — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$3.6B
Company size
EV
$3.7B
Debt-adjusted value
P/S
12.2
Premium
P/B
16.1
Premium
EV/Sales
12.5
Premium
FCF Yield
-0.82%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Strong
●
Profitability
Negative
≈
Cash Flow
Recovering
⚖
Balance Sheet
Manageable
💵 Revenue
70.87M
↗ Strong
📈 Net Income
-20.02M
↘ Negative
🧮 EPS (Basic)
-0.13
↘ Negative
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Related Opportunities